NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

連續生產設備供應商市場(針對小分子藥物和生物製藥)

Continuous Manufacturing Equipment Providers Market: Distribution by Type of Molecule (Small Molecule and Biologics), Type of Equipment (Mixers, Granulators, Dryers, Bioreactors / Reactors and Others), Stage of Manufacturing

出版商 Roots Analysis 商品編碼 1008225
出版日期 內容資訊 英文 254 Pages
商品交期: 最快1-2個工作天內
價格
連續生產設備供應商市場(針對小分子藥物和生物製藥) Continuous Manufacturing Equipment Providers Market: Distribution by Type of Molecule (Small Molecule and Biologics), Type of Equipment (Mixers, Granulators, Dryers, Bioreactors / Reactors and Others), Stage of Manufacturing
出版日期: 2021年03月31日內容資訊: 英文 254 Pages
簡介

藥品生產過程複雜、耗時且成本高。事實上,生產效率低下和產品召回(由於製造錯誤)估計每年造成約 500 億美元的損失。鑑於對藥物干預的需求不斷增長以及新的複雜療法的引入,API 製造商正在逐漸選擇更先進的製造解決方案,例如連續流動系統。

本報告對連續生產設備供應商市場進行調查和分析,並提供有關當前市場狀況和未來潛力的系統信息。

目錄

第 1 章前言

第 2 章執行摘要

第 3 章介紹

第 4 章小分子藥物連續生產設備:市場現狀

  • 章節概述
  • 小分子藥物連續生產設施:整體市場情況
  • 小分子藥物的連續生產設施:開發商情況

第 5 章生物製藥連續生產設備:市場現狀

  • 章節概述
  • 生物製藥連續生產設備:整體市場情況
  • 生物製藥連續生產設備:開發商情況

第6 章小分子藥物連續生產設備:企業簡介

  • 章節概述
  • Corning
  • Glatt
  • IKA
  • Kilburn Engineering
  • Thermo Fisher Scientific

第七章生物製藥連續生產設備:企業概況

  • 章節概述
  • Eppendorf
  • Merck Millipore
  • Pall
  • Sartorius
  • TA Instruments

第八章專利分析

  • 章節概述
  • 調查範圍/方法
  • 連續生產技術:專利分析

第九章企業競爭力分析

  • 章節概述
  • 調查方法及主要參數
  • 小分子藥物連續生產設備供應商
  • 生物製藥連續生產設備供應商

第 10 章案例研究:具有持續生產專業知識的公司

  • 情況和背景
  • 連續生產的早期採用者
  • 具有持續生產專業知識的公司
  • 結論

第11章市場規模和機會分析

  • 章節概述
  • 主要前提和預測方法
  • 全球連續生產設備供應商市場
  • 連續生產設備供應商市場分佈:按分子類型
  • 連續生產設備供應商市場-分佈:按設備類型
  • 連續生產設備供應商市場-分佈:按製造工藝類型
  • 連續生產設備供應商市場-分佈:按經營規模
  • 連續生產設備供應商市場-分佈:按地區

第12章結論

第十三章採訪實錄

第十四章附錄1:表格數據

第 15 章附錄 2:公司/組織名單

目錄

Title:
Continuous Manufacturing Equipment Providers Market:
Distribution by Type of Molecule (Small Molecule and Biologics), Type of Equipment (Mixers, Granulators, Dryers, Bioreactors / Reactors and Others), Stage of Manufacturing (Upstream Process and Downstream Process), Scale of Manufacturing (Preclinical / Clinical and Commercial) and Geography (North America, Europe and Asia Pacific): Industry Trends and Global Forecast, 2021-2030.

Overview:

Pharmaceutical manufacturing processes are complex, time consuming, as well as cost intensive. In fact, it is estimated that production inefficiencies and product recalls (owing to manufacturing errors) are responsible for annual losses amounting to around USD 50 billion. Given the ever-increasing demand for pharmacological interventions, and the introduction of new and sophisticated therapeutic modalities, drug substance manufacturers are gradually opting for more advanced manufacturing solutions, such as continuous flow systems. When compared to the conventional batch manufacturing process, the continuous mode of production has been demonstrated to allow significant cost savings (around 40% to 50% of expenditure when using traditional equipment) . According to the USFDA, using the continuous approach, it is even possible for industry stakeholders to significantly abbreviate production time; for instance, a drug that previously required a month to manufacture, can now be produced in a single day. Continuous processing also enables manufacturers to circumvent concerns related to equipment downtime, and use the entire capacity of production lines, while simultaneously testing the quality of products / production intermediates. Moreover, a continuous manufacturing facility requires 70% less area than a plant that is designed for running batch processes; this enables additional savings, in terms of facility operation costs. Further, continuous manufacturing processes can be automated, and the affiliated equipment usually includes a variety of advanced features that offer real-time visibility on various important parameters. Overall, the adoption of continuous flow technologies is believed to possess the potential to notably improve productivity, while minimizing batch-to-batch variability. So far, the US FDA has approved four therapies that were produced using the continuous manufacturing approach. In addition, there are over 20 product candidates that are currently being manufactured via the same approach.

Considering the various advantages of continuous manufacturing, pharmaceutical developers are gradually becoming more receptive to adopting such solutions. As a matter of fact, the recent surge in demand for pharmaceuticals amidst the COVID-19 pandemic, has served to create a strong case for pharmaceutical companies to develop the means to produce drugs faster. Moreover, the Centre for Drug Evaluation and Research (CDER) and US Biomedical Advanced Research and Development Authority (BRADA), are currently working closely to promote the use of continuous manufacturing for the production of therapeutics for medical emergencies. As a result, several industry stakeholders that are involved in drug development and production, have already made significant investments towards acquiring continuous manufacturing capabilities and the associated expertise. On the other hand, there are several companies that are now offering continuous manufacturing equipment that contain process analytical technologies (PAT) and advanced sensors. Further, many innovators claim to be engaged in improving the continuous manufacturing process, developing advanced variants of currently available processing systems, and optimizing on the cost of such solutions. The aforementioned developments are anticipated to result in an increase in adoption of continuous processing technologies, over the coming years.

Scope of the Report:

The "Continuous Manufacturing Equipment Providers Market by Type of Molecule (Small Molecules and Biologics), Type of Equipment (Mixers, Granulators, Bioreactors / Reactors and Others), Stage of Manufacturing (Upstream and Downstream Process), Scale of Operation (Preclinical / Clinical and Commercial) and Geography (North America, Europe and Asia Pacific), 2021-2030" report offers an elaborate study of the current scenario and future potential of the continuous manufacturing equipment providers market. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of continuous manufacturing equipment for small molecule drugs, along with information on type of equipment, type of manufacturing process (only continuous and batch continuous), stage of manufacturing (upstream process and downstream process), scale of operation (preclinical / clinical and commercial) and type of product (single purpose and multipurpose equipment). In addition, the chapter highlights the analysis of equipment provider(s), based on various parameters, such as year of establishment, company size, location of headquarters and key players.
  • A detailed assessment of the current market landscape of continuous manufacturing equipment for biologic drugs, providing information on type of equipment, type of manufacturing process (only continuous and batch continuous), stage of manufacturing (upstream process and downstream process) and scale of operation (preclinical / clinical and commercial). In addition, the chapter highlights the distribution of equipment provider(s), based on various parameters, such as year of establishment, company size, location of headquarters and key players.
  • An in-depth analysis of the various patents filed / granted related to continuous manufacturing and affiliated equipment, till 2020, along with information on key parameters, such as publication year, geography, CPC symbols, emerging focus areas, type of applicant and leading industry / non-industry players (in terms of size of intellectual property portfolio) . Further, it features a 3-D bubble analysis (based on publication year, patent citation count and extended geographical reach) and a detailed patent valuation analysis.
  • An insightful 4-D representation, highlighting the competitiveness analysis of continuous manufacturing equipment providers for small molecules and biologics, across key geographical areas, taking into consideration the company experience (experience of the company) , product expertise (scale of operation, type of manufacturing process, types of equipment and type of product) , product portfolio (number of equipment) and company size (small, mid-sized and large companies) .
  • A case study highlighting the contract manufacturing organizations that claim to have the required expertise and capabilities related to continuous manufacturing, along with information on relevant parameters, such as year of establishment, company size, purpose of manufacturing (in-house and contract service) , scale of operation (preclinical, clinical and commercial) , type of drug molecule, location of headquarters and location of continuous manufacturing facilities.
  • Tabulated profiles of key companies (shortlisted based on number of equipment provided) providing continuous manufacturing equipment for small molecules and biologics manufacturing. Each profile provides an overview of the company, list of continuous manufacturing equipment, financial information (if available), and details on recent developments as well as an informed future outlook.

One of the key objectives of the report was to estimate the existing market size and future potential of the continuous manufacturing equipment providers market over the coming years. We have provided an informed estimate to the likely evolution of the market in the short to mid-term and long term, for the period of 2021-2030. Our year-wise projections of the current and future opportunity have further been segmented based on [A] type of molecule (small molecule and biologic), [B] type of equipment (mixers, granulators, bioreactors / reactors and others), [C] scale of operation (preclinical / clinical and commercial), stage of manufacturing (upstream and downstream process) and [D] geography (North America, Europe and Asia Pacific).

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Andrea Adamo (Founder and Chief Executive Officer, Zaiput Flow Technologies)
  • Bayan Takizawa (Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals)
  • Graeme Cruickshank (Chief Technology and Innovation Officer, Center for Process Innovation)
  • Nick Thomson (Senior Director Chemical Research and Development, Pfizer)
  • Anonymous (Senior Manager, Continuous Manufacturing Business Development, Patheon)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the key players engaged in offering continuous manufacturing equipment for small molecule and biologic drugs?
  • What are the current regulatory requirements for continuous manufacturing, across different geographies?
  • How is the intellectual property landscape likely to evolve in the foreseen future?
  • What factors are likely to influence the evolution of the continuous manufacturing equipment providers market?
  • How is the current and future opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of continuous manufacturing equipment providers market and its likely evolution in the short-mid and long term.

Chapter 3 is an introductory chapter that highlights important concepts related to continuous manufacturing, including a discussion on the emergence of continuous equipment and technologies, and type of continuous manufacturing equipment presently available in the market. It further elaborates on the advantages offered by the continuous manufacturing technique, key quality / cGMP considerations, challenges associated with continuous manufacturing equipment, overview of existing regulatory guidelines and the future perspectives related to continuous manufacturing equipment.

Chapter 4 includes information on close to 380 continuous manufacturing equipment for small molecule drugs. It features a detailed analysis on type of equipment, type of manufacturing process (only continuous and batch-continuous) and stage of manufacturing (upstream process and downstream process). The chapter also features scale of operation (preclinical / clinical and commercial) and type of product (multipurpose and single purpose). Further, the chapter provides information on equipment provider(s), highlighting their year of establishment, company size, location of headquarters and key players in this domain.

Chapter 5 includes information on more than 80 continuous manufacturing equipment for biologics. It features a detailed analysis on type of equipment, type of manufacturing process (only continuous and batch-continuous) and stage of manufacturing (upstream process and downstream process). The chapter also features analysis on the scale of operation (preclinical / clinical and commercial). Further, the chapter provides information on equipment provider(s) along with information on year of establishment, company size, location of headquarters and key players in this domain.

Chapter 6 features tabulated profiles of key companies (shortlisted based on maximum number of equipment provided) providing continuous manufacturing equipment for small molecule drugs. Each profile provides an overview of the company, list of continuous manufacturing equipment, financial information (if available), and details on recent developments as well as an informed future outlook.

Chapter 7 features tabulated profiles of key companies (shortlisted based on maximum number of equipment provided) providing continuous manufacturing equipment for biologic drugs. Each profile provides an overview of the company, list of continuous manufacturing equipment, financial information (if available), and details on recent developments as well as an informed future outlook.

Chapter 8 presents an in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing and affiliated equipment till 2020. It includes information on key parameters such as their publication year, geographical location, CPC symbol, emerging focus areas, type of applicant and leading industry / non-industry players (in terms of size of intellectual property portfolio). It also features a 3-D bubble analysis (based on publication year, patent citation count and extended geographical reach) and a detailed valuation analysis.

Chapter 9 features a chapter on an insightful 4-D representation, highlighting the competitiveness analysis of continuous manufacturing equipment providers for small molecules and biologics across key geographical areas, taking into consideration company experience (experience of the company), product expertise (scale of operation, type of manufacturing process, types of equipment and type of product), product portfolio (number of equipment) and company size (small, mid-sized and large companies).

Chapter 10 presents a case study on the contract manufacturing organizations having the required expertise and capabilities for continuous manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, purpose of manufacturing (in-house and contract service), scale of operation (preclinical, clinical and commercial), location of headquarter, location of continuous manufacturing facilities and type of drug molecule.

Chapter 11 presents a comprehensive market forecast analysis, highlighting the likely growth of continuous manufacturing equipment providers market, 2021 - 2030. The chapter provides likely distribution of the projected future opportunity based on type of molecule (small molecule and biologic), type of equipment (mixers, granulators, bioreactors / reactors and others), scale of operation (preclinical / clinical and commercial), stage of manufacturing (upstream and downstream process) and geography (North America, Europe and Asia Pacific).

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers an independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 14 is a collection of executive insights of the discussion that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interview held with Andrea Adamo (Founder and Chief Executive Officer, Zaiput Flow Technologies), Bayan Takizawa (Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals), Graeme Cruickshank (Chief Technology and Innovation Officer, Center for Process Innovation), Nick Thomson (Senior Director Chemical Research and Development, Pfizer) and Anonymous (Senior Manager, Continuous Manufacturing Business Development, Patheon Pharma Services).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Continuous Manufacturing and Affiliated Technologies
  • 3.3. Types of Continuous Manufacturing Equipment
  • 3.4. Advantages of Continuous Manufacturing
  • 3.5. Quality (cGMP) Considerations
  • 3.6. Challenges Associated with Continuous Manufacturing Equipment
  • 3.7. Future Perspectives

4. CONTINUOUS MANUFACTURING EQUIPMENT FOR SMALL MOLECULE DRUGS: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Continuous Manufacturing Equipment for Small Molecule Drugs: Overall Market Landscape
    • 4.2.1. Analysis by Type of Equipment
    • 4.2.2. Analysis by Type of Manufacturing Process
    • 4.2.3. Analysis by Stage of Manufacturing
    • 4.2.4. Analysis by Scale of Operation
    • 4.2.5. Analysis by Type of Product
  • 4.3. Continuous Manufacturing Equipment for Small Molecule Drugs: Developer Landscape
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters
    • 4.3.4. Key Continuous Manufacturing Equipment Providers

5. CONTINUOUS MANUFACTURING EQUIPMENT FOR BIOLOGIC DRUGS: MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Continuous Manufacturing Equipment for Biologic Drugs: Overall Market Landscape
    • 5.2.1. Analysis by Type of Equipment
    • 5.2.2. Analysis by Type of Manufacturing Process
    • 5.2.3. Analysis by Stage of Manufacturing
    • 5.2.4. Analysis by Scale of Operation
  • 5.3. Continuous Manufacturing Equipment for Biologic Drugs: Developer Landscape
    • 5.3.1. Analysis by Year oaf Establishment
    • 5.3.2. Analysis by Company Size
    • 5.3.3. Analysis by Location of Headquarters
    • 5.3.4. Key Continuous Manufacturing Equipment Providers

6. CONTINUOUS MANUFACTURING EQUIPMENT FOR SMALL MOLECULE DRUGS: COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2 Corning
    • 6.2.1. Company Overview
    • 6.2.2. Recent Developments and Future Outlook
  • 6.3. Glatt
    • 6.3.1. Company Overview
    • 6.3.2. Recent Developments and Future Outlook
  • 6.4. IKA
    • 6.4.1. Company Overview
    • 6.4.2. Recent Developments and Future Outlook
  • 6.5. Kilburn Engineering
    • 6.5.1. Company Overview
    • 6.5.2. Recent Developments and Future Outlook
  • 6.6. Thermo Fisher Scientific
    • 6.6.1. Company Overview
    • 6.6.2. Recent Developments and Future Outlook

7. CONTINUOUS MANUFACTURING EQUIPMENT FOR BIOLOGIC DRUGS: COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. Eppendorf
    • 7.2.1. Company Overview
    • 7.2.2. Recent Developments and Future Outlook
  • 7.3. Merck Millipore
    • 7.3.1. Company Overview
    • 7.3.2. Recent Developments and Future Outlook
  • 7.4. Pall
    • 7.4.1. Company Overview
    • 7.4.2. Recent Developments and Future Outlook
  • 7.5. Sartorius
    • 7.5.1. Company Overview
    • 7.5.2. Recent Developments and Future Outlook
  • 7.6. TA Instruments
    • 7.6.1. Company Overview
    • 7.6.2. Recent Developments and Future Outlook

8. PATENT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Continuous Manufacturing Technologies: Patent Analysis
    • 8.3.1. Analysis by Publication Year
    • 8.3.2. Analysis by Geography
    • 8.3.3. Analysis by CPC Symbols
    • 8.3.4. Emerging Focus Areas
    • 8.3.5. Analysis by Type of Applicant
    • 8.3.6. Leading Players: Analysis by Number of Patents
    • 8.3.7. Analysis by Patent Publication Year, Patent Citation Count and Extended Family Size
    • 8.3.8. Patent Valuation Analysis by Patent Age, Number of Citation and Geographical Reach
      • 8.3.8.1. Leading Patents: Information by Number of Citations

9. COMPANY COMPETITIVENESS ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Methodology and Key Parameters
  • 9.3. Continuous Manufacturing Equipment Providers for Small Molecule Drugs
    • 9.3.1. Companies based in North America
    • 9.3.2. Companies based in Europe
    • 9.3.3. Companies based in Asia Pacific
    • 9.3.4. Key Players: Analysis by Company Experience, Product Expertise, Product Portfolio and Key Market Presence
  • 9.4. Continuous Manufacturing Equipment Providers for Biologic Drugs
    • 9.4.1. Companies based in North America
    • 9.4.2. Companies based in Rest of the World (Europe and Asia Pacific)
    • 9.4.3. Key Players: Analysis by Company Experience, Product Expertise, Product Portfolio and Key Market Presence

10. CASE STUDY: COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING

  • 10.1. Context and Background
  • 10.2. Early Adopters of Continuous Manufacturing
  • 10.3. Companies with Expertise in Continuous Manufacturing
    • 10.3.1. Analysis by Year of Establishment
    • 10.3.2. Analysis by Company Size
    • 10.3.3. Analysis by Purpose of Manufacturing
    • 10.3.4. Analysis by Scale of Operation
    • 10.3.5. Analysis by Type of Drug Molecule
    • 10.3.6. Analysis by Location of Headquarters
    • 10.3.7. Analysis by Year of Establishment and Company Size (Logo Landscape)
    • 10.3.8. Analysis by Location of Continuous Drug Manufacturing Facilities
  • 10.4. Concluding Remarks

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Key Assumptions and Forecast Methodology
  • 11.3. Global Continuous Manufacturing Equipment Providers Market, 2021-2030
  • 11.4. Continuous Manufacturing Equipment Providers Market, 2021-2030: Distribution by Type of Molecule
    • 11.4.1. Continuous Manufacturing Equipment Providers Market for Small Molecule Drugs, 2021-2030
    • 11.4.2. Continuous Manufacturing Equipment Providers Market for Biologics, 2021-2030
  • 11.5. Continuous Manufacturing Equipment Providers Market, 2021-2030: Distribution by Type of Equipment
    • 11.5.1. Continuous Manufacturing Equipment Providers Market for Mixers, 2021-2030
    • 11.5.2. Continuous Manufacturing Equipment Providers Market for Granulators, 2021-2030
    • 11.5.3. Continuous Manufacturing Equipment Providers Market for Dryers, 2021-2030
    • 11.5.4. Continuous Manufacturing Equipment Providers Market for Bioreactors / Reactors, 2021-2030
    • 11.5.5. Continuous Manufacturing Equipment Providers Market for Other Equipment, 22021-2030
  • 11.6. Continuous Manufacturing Equipment Providers Market, 2021-2030: Distribution by Type of Manufacturing Process
    • 11.6.1. Continuous Manufacturing Equipment Providers Market for Upstream Process, 2021-2030
    • 11.6.2. Continuous Manufacturing Equipment Providers Market for Downstream Process, 2021-2030
  • 11.7. Continuous Manufacturing Equipment Providers Market, 2021-2030: Distribution by Scale of Operation
    • 11.7.1. Continuous Manufacturing Equipment Providers Market for Preclinical / Clinical Scale Operations, 2021-2030
    • 11.7.2. Continuous Manufacturing Equipment Providers Market for Commercial Scale Operations, 2021-2030
  • 11.8. Continuous Manufacturing Equipment Providers Market, 2021-2030: Distribution by Type of Geography
    • 11.8.1. Continuous Manufacturing Equipment Providers Market in North America, 2021-2030
    • 11.8.2. Continuous Manufacturing Equipment Providers Market in Europe, 2021-2030
    • 11.8.3. Continuous Manufacturing Equipment Providers Market in Asia Pacific, 2021-2030

12. CONCLUDING REMARKS

  • 12.1. Chapter Overview
  • 12.2. Key Takeaway

13. INTERVIEW TRANSCRIPTS

  • 13.1. Chapter Overview
  • 13.2. Andrea Adamo, Founder and Chief Executive Officer, Zaiput Flow Technologies
  • 13.3. Bayan Takizawa, Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals
  • 13.4. Graeme Cruickshank, Chief Technology and Innovation Officer, Centre for Process Innovation
  • 13.5. Nick Thomson, Senior Director Chemical Research and Development, Pfizer
  • 13.6. Anonymous, Senior Manager, Continuous Manufacturing Business Development, Patheon

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Comparison between Batch and Integrated Continuous Manufacturing Processes
  • Figure 3.2 Types of Continuous Manufacturing Equipment
  • Figure 4.1 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Type of Equipment
  • Figure 4.2 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Type of Manufacturing Process
  • Figure 4.3 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Stage of Manufacturing
  • Figure 4.4 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Scale of Operation
  • Figure 4.5 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Type of Product
  • Figure 4.6 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Distribution by Year of Establishment
  • Figure 4.7 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Distribution by Company Size
  • Figure 4.8 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Distribution by Location of Headquarters
  • Figure 4.9 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Key Players
  • Figure 5.1 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Equipment
  • Figure 5.2 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Manufacturing Process
  • Figure 5.3 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Stage of Manufacturing
  • Figure 5.4 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Scale of Operation
  • Figure 5.5 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Year of Establishment
  • Figure 5.6 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Company Size
  • Figure 5.7 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Location of Headquarters
  • Figure 5.8 Continuous Manufacturing Equipment Providers for Biologic Drugs: Key Players
  • Figure 8.1 Patent Analysis: Distribution by Type of Patent
  • Figure 8.2 Patent Analysis: Cumulative Year-wise Trend
  • Figure 8.3 Patent Analysis: Distribution by Region
  • Figure 8.4 Patent Analysis: Distribution by CPC Symbols
  • Figure 8.5 Patent Analysis: Distribution of CPC Symbols by Publication Year
  • Figure 8.6 Patent Analysis: Emerging Focus Areas
  • Figure 8.7 Patent Analysis: Distribution by Type of Applicant
  • Figure 8.8 Leading Industry Players: Distribution by Number of Patents
  • Figure 8.9 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 8.10 3-D Bubble Analysis: Distribution by Publication Year, Citation Count and Extended Geographical Family
  • Figure 8.11 Patent Analysis: Distribution by Patent Age, 2000- 2020 (till November)
  • Figure 8.12 Patent Analysis: Distribution by Region, Pre 2014 - 2020 (till November)
  • Figure 8.13 Continuous Manufacturing Technologies for Pharmaceuticals: Patent Valuation
  • Figure 9.1 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Small Molecules in North America
  • Figure 9.2 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Small Molecules in Europe
  • Figure 9.3 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Small Molecules in Asia Pacific
  • Figure 9.4 Continuous Manufacturing Equipment Providers for Small Molecules: Key Players
  • Figure 9.5 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Biologics in North America
  • Figure 9.6 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Biologics in RoW
  • Figure 9.7 Continuous Manufacturing Equipment Providers for Biologics: Key Players
  • Figure 10.1 Continuous Drug Manufacturers: Distribution by Year of Establishment
  • Figure 10.2 Continuous Drug Manufacturers: Distribution by Company Size
  • Figure 10.3 Continuous Drug Manufacturers: Distribution by Purpose of Manufacturing
  • Figure 10.4 Continuous Drug Manufacturers: Distribution by Scale of Operation
  • Figure 10.5 Continuous Drug Manufacturers: Distribution by Location of Headquarters
  • Figure 10.6 Continuous Drug Manufacturers: Distribution by Year of Establishment and Company Size
  • Figure 10.7 Continuous Drug Manufacturers: Distribution by Location of Facilities
  • Figure 10.8 Continuous Drug Manufacturers: Distribution by Type of Drug
  • Figure 12.1 Global Continuous Manufacturing Equipment Providers Market, 2021-2030
  • Figure 12.2 Global Continuous Manufacturing Equipment Providers Market for Small Molecules, 2021-2030
  • Figure 12.3 Global Continuous Manufacturing Equipment Providers Market for Biologics, 2021-2030
  • Figure 12.4 Continuous Manufacturing Equipment Providers Market for Mixers, 2021-2030
  • Figure 12.5 Continuous Manufacturing Equipment Providers Market for Granulators, 2021-2030
  • Figure 12.6 Continuous Manufacturing Equipment Providers Market for Dryers, 2021-2030
  • Figure 12.7 Continuous Manufacturing Equipment Providers Market for Bioreactors / Reactors, 2021-2030
  • Figure 12.8 Continuous Manufacturing Equipment Providers Market for Other Equipment, 2021-2030
  • Figure 12.9 Continuous Manufacturing Equipment Providers Market for Upstream Process, 2021-2030
  • Figure 12.10 Continuous Manufacturing Equipment Providers Marker for Downstream Process, 2021-2030
  • Figure 12.11 Continuous Manufacturing Equipment Providers Market for Preclinical / Clinical Operations, 2021-2030
  • Figure 12.12 Continuous Manufacturing Equipment Providers Market for Commercial Operations, 2021-2030
  • Figure 12.13 Continuous Manufacturing Equipment Providers Market in North America, 2021-2030
  • Figure 12.14 Continuous Manufacturing Equipment Providers Market in Europe, 2021-2030
  • Figure 12.15 Continuous Manufacturing Equipment Providers Market in Asia Pacific, 2021-2030

List Of Tables

  • Table 3.1 Batch versus Continuous Manufacturing Technology: Comparison of Key Characteristics
  • Table 4.1 Continuous Manufacturing Equipment for Small Molecules: Information on Type of Equipment, Type of Manufacturing Process and Stage of Manufacturing
  • Table 4.2 Continuous Manufacturing Equipment for Small Molecules: Information on Scale of Operation, Type of Product and Throughput / Capacity
  • Table 4.3 Continuous Manufacturing Equipment Providers for Small Molecules: Information of Year of Establishment, Company Size and Location of Headquarters
  • Table 5.1 Continuous Manufacturing Equipment for Biologics: Information on Type of Equipment, Type of Manufacturing Process and Stage of Manufacturing
  • Table 5.2 Continuous Manufacturing Equipment for Biologics: Information on Scale of Operation and Throughput / Capacity
  • Table 5.3 Continuous Manufacturing Equipment Providers for Biologics: Information of Year of Establishment, Company Size and Location of Headquarters
  • Table 6.1 Corning: Company Snapshot
  • Table 6.2 Corning: Recent Developments and Future Outlook
  • Table 6.3 Glatt: Company Snapshot
  • Table 6.4 Glatt: Recent Developments and Future Outlook
  • Table 6.5 IKA: Company Snapshot
  • Table 6.6 Kilburn Engineering: Company Snapshot
  • Table 6.7 Thermo Fisher Scientific: Company Snapshot
  • Table 6.8 Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 7.1 Eppendorf: Company Snapshot
  • Table 7.2 Eppendorf: Recent Developments and Future Outlook
  • Table 7.3 Merck Millipore: Company Snapshot
  • Table 7.4 Merck Millipore: Recent Developments and Future Outlook
  • Table 7.5 Pall: Company Snapshot
  • Table 7.6 Pall: Recent Developments and Future Outlook
  • Table 7.7 Sartorius: Company Snapshot
  • Table 7.8 Sartorius: Recent Developments and Future Outlook
  • Table 7.9 TA Instruments: Company Snapshot
  • Table 7.10 TA Instruments: Recent Developments and Future Outlook
  • Table 8.1 Patent Analysis: Prominent CPC Symbols
  • Table 8.2 Patent Analysis: Most Popular CPC Symbols
  • Table 8.3 Patent Analysis: Top CPC Symbols
  • Table 8.4 Patent Valuation Analysis: Categorization based on Proprietary Scoring Criteria
  • Table 8.5 Patent Analysis: Distribution by Number of Citations
  • Table 10.1 Continuous Drug Manufacturers: Information on Year of Establishment, Company Size, Purpose of Manufacturing, Scale of Operation and Location of Headquarters
  • Table 10.2 Continuous Drug Manufacturers: Information on Number and Location of Production Facilities
  • Table 10.3 Continuous Drug Manufacturers: Information on Type of Drug Manufactured
  • Table 13.1 Zaiput Flow Technologies: Company Snapshot
  • Table 13.2 CONTINUUS Pharmaceuticals: Company Snapshot
  • Table 13.3 Centre for Process Innovation: Company Snapshot
  • Table 13.4 Pfizer: Company Snapshot
  • Table 13.5 Patheon: Company Snapshot
  • Table 14.1 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Type of Equipment
  • Table 14.2 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Type of Manufacturing Process
  • Table 14.3 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Stage of Manufacturing
  • Table 14.4 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Scale of Operation
  • Table 14.5 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Type of Product
  • Table 14.6 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Distribution by Year of Establishment
  • Table 14.7 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Distribution by Company Size
  • Table 14.8 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Distribution by Location of Headquarters
  • Table 14.9 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Key Players
  • Table 14.10 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Equipment
  • Table 14.11 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Manufacturing Process
  • Table 14.12 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Stage of Manufacturing
  • Table 14.13 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Scale of Operation
  • Table 14.14 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Year of Establishment
  • Table 14.15 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Company Size
  • Table 14.16 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Location of Headquarters
  • Table 14.17 Continuous Manufacturing Equipment Providers for Biologic Drugs: Key Players
  • Table 14.18 Patent Analysis: Distribution by Type of Patent
  • Table 14.19 Patent Analysis: Cumulative Year-wise Trend
  • Table 14.20 Patent Analysis: Distribution by Geographical Region
  • Table 14.21 Patent Analysis: Distribution by CPC Symbols
  • Table 14.22 Patent Analysis: Distribution of CPC Symbols by Publication Year
  • Table 14.23 Patent Analysis: Emerging Focus Areas
  • Table 14.24 Patent Analysis: Distribution by Type of Applicant
  • Table 14.25 Leading Industry Players: Distribution by Number of Patents
  • Table 14.26 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 14.27 3-D Bubble Analysis: Distribution by Publication Year, Citation Count and Extended Geographical Family
  • Table 14.28 Patent Analysis: Distribution by Patent Age, 2000- 2020 (till November)
  • Table 14.29 Patent Analysis: Distribution by Region, Pre 2014 - 2020 (till November)
  • Table 14.30 Continuous Manufacturing Technologies for Pharmaceuticals: Patent Valuation
  • Table 14.31 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Small Molecules in North America
  • Table 14.32 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Small Molecules in Europe
  • Table 14.33 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Small Molecules in Asia Pacific
  • Table 14.34 Continuous Manufacturing Equipment Providers for Small Molecules: Key Players
  • Table 14.35 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Biologics in North America
  • Table 14.36 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Biologics in RoW
  • Table 14.37 Continuous Manufacturing Equipment Providers for Biologics: Key Players
  • Table 14.38 Continuous Drug Manufacturers: Distribution by Year of Establishment
  • Table 14.39 Continuous Drug Manufacturers: Distribution by Company Size
  • Table 14.40 Continuous Drug Manufacturers: Distribution by Purpose of Manufacturing
  • Table 14.41 Continuous Drug Manufacturers: Distribution by Scale of Operation
  • Table 14.42 Continuous Drug Manufacturers: Distribution by Location of Headquarters
  • Table 14.43 Continuous Drug Manufacturers: Distribution by Year of Establishment and Company Size
  • Table 14.44 Continuous Drug Manufacturers: Distribution by Location of Facilities
  • Table 14.45 Continuous Drug Manufacturers: Distribution by Type of Drug
  • Table 14.46 Global Continuous Manufacturing Equipment Providers Market, 2021-2030
  • Table 14.47 Global Continuous Manufacturing Equipment Providers Market for Small Molecules, 2021-2030
  • Table 14.48 Global Continuous Manufacturing Equipment Providers Market for Biologics, 2021-2030
  • Table 14.49 Continuous Manufacturing Equipment Providers Market for Mixers, 2021-2030
  • Table 14.50 Continuous Manufacturing Equipment Providers Market for Granulators, 2021-2030
  • Table 14.51 Continuous Manufacturing Equipment Providers Market for Dryers, 2021-2030
  • Table 14.51 Continuous Manufacturing Equipment Providers Market for Bioreactors / Reactors, 2021-2030
  • Table 14.52 Continuous Manufacturing Equipment Providers Market for Other Equipment, 2021-2030
  • Table 14.53 Continuous Manufacturing Equipment Providers Market for Upstream Process, 2021-2030
  • Table 14.54 Continuous Manufacturing Equipment Providers Marker for Downstream Process, 2021-2030
  • Table 14.55 Continuous Manufacturing Equipment Providers Market for Preclinical / Clinical Operations, 2021-2030
  • Table 14.56 Continuous Manufacturing Equipment Providers Market for Commercial Operations, 2021-2030
  • Table 14.57 Continuous Manufacturing Equipment Providers Market in North America, 2021-2030
  • Table 14.58 Continuous Manufacturing Equipment Providers Market in Europe, 2021-2030
  • Table 14.59 Continuous Manufacturing Equipment Providers Market in Asia Pacific, 2021-2030

List Of Companies

The following companies and organizations have been included in the report.

  • 1. 3D Biotek
  • 2. AbbVie
  • 3. Ajax Equipment
  • 4. Alexanderwerk
  • 5. Allgaier Process Technology
  • 6. Amgen
  • 7. amixon
  • 8. Applikon Biotechnology
  • 9. AstraZeneca
  • 10. AWL (Alconbury Weston Limited)
  • 11. Baker Perkins
  • 12. bbi-biotech
  • 13. Boeing
  • 14. Cell Culture Company
  • 15. Cellec Biotek
  • 16. Centre for Process Innovation
  • 17. Changzhou Ruide Drying Engineering Technology
  • 18. Chemtrix
  • 19. Commonwealth Scientific and Industrial Research Organization
  • 20. CONTINUUS Pharmaceuticals
  • 21. Coperion
  • 22. Corning
  • 23. Cytiva
  • 24. DCI-Biolafitte
  • 25. Design Integrated Technology
  • 26. DEVEX Verfahrenstechnik
  • 27. DRIAM
  • 28. Eli Lilly
  • 29. Eppendorf
  • 30. Evaporators & Dryers Engineering
  • 31. Florida State University
  • 32. Freund
  • 33. GEA
  • 34. Gericke
  • 35. Gilead Sciences
  • 36. Glatt
  • 37. Hosokawa Micron Powder Systems
  • 38. Hovione
  • 39. IKA
  • 40. Iowa Mixing and Process Equipment Company
  • 41. Janssen
  • 42. Jaygo
  • 43. Kemutec
  • 44. Kevin Process Technologies
  • 45. Kilburn Engineering
  • 46. KORSCH
  • 47. Kurimoto
  • 48. L.B. Bohle
  • 49. LCI
  • 50. Lödige Process Technology
  • 51. Massachusetts Institute of Technology
  • 52. Merck
  • 53. Metso
  • 54. Munson Machinery
  • 55. Neuhaus Neotec
  • 56. NiTech Solutions
  • 57. Novartis
  • 58. E.T. Oakes
  • 59. O'Hara Technologies
  • 60. OmniBRx Biotechnologies
  • 61. Pall Life Sciences
  • 62. Patheon
  • 63. Pfizer
  • 64. Pierre Guerin
  • 65. Proton Engineers
  • 66. Purdue University
  • 67. Puschner
  • 68. Readco Kurimoto
  • 69. Repligen
  • 70. Riera Nadeu
  • 71. Shuanglong Group
  • 72. S. Howes
  • 73. SaintyCo
  • 74. Saka Engineering Systems
  • 75. Sartorius
  • 76. Scott Equipment Company
  • 77. Semba Biosciences
  • 78. Senieer
  • 79. Shachi Engineering
  • 80. Shree Bhagwati Machtech
  • 81. Buss-SMS-Canzler
  • 82. Sonic
  • 83. SPX FLOW
  • 84. Stalam
  • 85. STEERLife
  • 86. Sturtevant
  • 87. symex
  • 88. Syntegon
  • 89. Synthecon
  • 90. TA Instruments
  • 91. Tema Process
  • 92. The Young Industries
  • 93. Thermo Fisher Scientific
  • 94. Thomas
  • 95. Uni-Mech Industries
  • 96. University of California
  • 97. University of Illinois
  • 98. Vapourtec
  • 99. Vertex
  • 100. XPure
  • 101. Yenchen Machinery
  • 102. YMC Process Technologies
  • 103. Zaiput Flow Technologies